These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 16570921

  • 1. Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.
    McDonald IM, Austin C, Buck IM, Dunstone DJ, Griffin E, Harper EA, Hull RA, Kalindjian SB, Linney ID, Low CM, Pether MJ, Spencer J, Wright PT, Adatia T, Bashall A.
    J Med Chem; 2006 Apr 06; 49(7):2253-61. PubMed ID: 16570921
    [Abstract] [Full Text] [Related]

  • 2. Achiral, selective CCK2 receptor antagonists based on a 1,3,5-benzotriazepine-2,4-dione template.
    Spencer J, Gaffen J, Griffin E, Harper EA, Linney ID, McDonald IM, Roberts SP, Shaxted ME, Adatia T, Bashall A.
    Bioorg Med Chem; 2008 Mar 15; 16(6):2974-83. PubMed ID: 18289857
    [Abstract] [Full Text] [Related]

  • 3. Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion.
    McDonald IM, Black JW, Buck IM, Dunstone DJ, Griffin EP, Harper EA, Hull RA, Kalindjian SB, Lilley EJ, Linney ID, Pether MJ, Roberts SP, Shaxted ME, Spencer J, Steel KI, Sykes DA, Walker MK, Watt GF, Wright L, Wright PT, Xun W.
    J Med Chem; 2007 Jun 28; 50(13):3101-12. PubMed ID: 17536796
    [Abstract] [Full Text] [Related]

  • 4. Discovery and characterization of novel, potent, non-peptide parathyroid hormone-1 receptor antagonists.
    McDonald IM, Austin C, Buck IM, Dunstone DJ, Gaffen J, Griffin E, Harper EA, Hull RA, Kalindjian SB, Linney ID, Low CM, Patel D, Pether MJ, Raynor M, Roberts SP, Shaxted ME, Spencer J, Steel KI, Sykes DA, Wright PT, Xun W.
    J Med Chem; 2007 Oct 04; 50(20):4789-92. PubMed ID: 17850061
    [Abstract] [Full Text] [Related]

  • 5. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors.
    Escherich A, Lutz J, Escrieut C, Fourmy D, van Neuren AS, Müller G, Schafferhans A, Klebe G, Moroder L.
    Biopolymers; 2007 Oct 04; 56(2):55-76. PubMed ID: 11592053
    [Abstract] [Full Text] [Related]

  • 6. 5-(tryptophylamino)-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based cholecystokinin receptor antagonists: reversal of CCK1 receptor subtype selectivity toward CCK2 receptors.
    Muñoz-Ruiz P, García-López MT, Cenarruzabeitia E, Del Río J, Dufresne M, Foucaud M, Fourmy D, Herranz R.
    J Med Chem; 2004 Oct 07; 47(21):5318-29. PubMed ID: 15456276
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors.
    Akgün E, Körner M, Gao F, Harikumar KG, Waser B, Reubi JC, Portoghese PS, Miller LJ.
    J Med Chem; 2009 Apr 09; 52(7):2138-47. PubMed ID: 19271701
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
    Lee YS, Agnes RS, Badghisi H, Davis P, Ma SW, Lai J, Porreca F, Hruby VJ.
    J Med Chem; 2006 Mar 09; 49(5):1773-80. PubMed ID: 16509592
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists.
    Henke BR, Aquino CJ, Birkemo LS, Croom DK, Dougherty RW, Ervin GN, Grizzle MK, Hirst GC, James MK, Johnson MF, Queen KL, Sherrill RG, Sugg EE, Suh EM, Szewczyk JW, Unwalla RJ, Yingling J, Willson TM.
    J Med Chem; 1997 Aug 15; 40(17):2706-25. PubMed ID: 9276016
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.
    Tsukamoto I, Koshio H, Kuramochi T, Saitoh C, Yanai-Inamura H, Kitada-Nozawa C, Yamamoto E, Yatsu T, Shimada Y, Sakamoto S, Tsukamoto S.
    Bioorg Med Chem; 2009 Apr 15; 17(8):3130-41. PubMed ID: 19321349
    [Abstract] [Full Text] [Related]

  • 17. Benzotriazonine as a new core structure for the design of CCK-receptor antagonists.
    Escherich A, Escrieut C, Fourmy D, Moroder L.
    J Pept Sci; 1999 Mar 15; 5(3):155-8. PubMed ID: 10323559
    [Abstract] [Full Text] [Related]

  • 18. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent.
    Hirst GC, Aquino C, Birkemo L, Croom DK, Dezube M, Dougherty RW, Ervin GN, Grizzle MK, Henke B, James MK, Johnson MF, Momtahen T, Queen KL, Sherrill RG, Szewczyk J, Willson TM, Sugg EE.
    J Med Chem; 1996 Dec 20; 39(26):5236-45. PubMed ID: 8978852
    [Abstract] [Full Text] [Related]

  • 19. Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor.
    Hadac EM, Dawson ES, Darrow JW, Sugg EE, Lybrand TP, Miller LJ.
    J Med Chem; 2006 Feb 09; 49(3):850-63. PubMed ID: 16451051
    [Abstract] [Full Text] [Related]

  • 20. Effect of lipopolysaccharide on expression and characterization of cholecystokinin receptors in rat pulmonary interstitial macrophages.
    Xu SJ, Gao WJ, Cong B, Yao YX, Gu ZY.
    Acta Pharmacol Sin; 2004 Oct 09; 25(10):1347-53. PubMed ID: 15456538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.